Resources

Select from the drop-down menu below to read the most up-to-date news about pelareorep.

September 19, 2024 | Media Coverage
Cancer Network: Pelareorep Combo Yields Survival Benefit in HR+/HER2- Breast Cancer
September 19, 2024 | Media Coverage
Targeted Oncology: Pelareorep Plus Paclitaxel Extends Survival in HR+/HER2- Breast Cancer
September 19, 2024 | Media Coverage
OncLive: Pelareorep Plus Chemo Improves OS in Endocrine-Refractory HR+/HER2- Advanced Breast Cancer
May 31, 2024 | Poster
Phase 1/2 Randomized, Open-label, Multicenter, Simon Two-stage Study of Pelareorep Combined with Modified FOLFIRINOX +/- Atezolizumab in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Arnold, Dirk et al, Previously presented at the 2024 American Society of Clinical Oncology Annual Meeting; 2024 May 31 – June 4
December 6, 2023 | Poster
T Cell Receptor Sequencing to Monitor Pelareorep-Induced Expansion of Tumor Infiltrating Lymphocytes 
Trauger, Richard et al, Previously presented at the 2023 San Antonio Breast Cancer Symposium®; December 5-9, 2023
November 9, 2023 | Poster
GOBLET: A phase 1/2 multiple indication study in advanced gastrointestinal cancers treated with pelareorep and atezolizumab – preliminary safety and efficacy results in second-line or later unresectable anal carcinoma
Arnold, Dirk et al. Previously presented at The 2nd International Multidisciplinary Anal Cancer Conference (IMACC) 2023, Nov. 9-10, 2023
November 3, 2023 | Poster
Analysis of the HR+/HER2- breast cancer tumor microenvironment following immune priming with pelareorep and atezolizumab using imaging mass cytometry – Results from the AWARE-1 trial
Olea, Julian et al. Previously presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, November 1-5, 2023
October 23, 2023 | Poster
Pelareorep (pela) + atezolizumab (atezo) and chemotherapy in first-line (1L) advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients – Results from the GOBLET study
Arnold, Dirk et al. Previously presented at ESMO Congress 2023, Oct. 23, 2023

Expanded Access

Oncolytics believes that participating in clinical trials is the best way for patients to access pelareorep. We are not currently able to fulfill expanded access requests at this time.

Information on many of Oncolytics clinical trials can be found at Home – ClinicalTrials.gov. If a treating physician would like additional information, the physician should directly contact Oncolytics at info@oncolytics.ca.

Information on many of Oncolytics clinical trials can be found at Home – ClinicalTrials.gov. If a treating doctor would like additional information, the doctor should formally contact Oncolytics at info@oncolytics.ca.

Contact Us

For questions regarding our science, partnership opportunities, or other inquiries, we encourage you to reach out.

Get in touch